Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 7/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409501 | 0.82 | FEN1 (0.57) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL8691780 | 0.81 | ALDH1A1 (0.58) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL7272179 | 0.77 | FEN1 (0.58) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL3516135 | 0.76 | FEN1 (0.46) | FEN1CYP2C19PDE4ALDHAKDM4E | |
| SCHEMBL11056945 | 0.74 | CDK4 (0.51) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL13407862 | 0.74 | FEN1 (0.49) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL17490150 | 0.74 | FEN1 (0.48) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL9800214 | 0.73 | FEN1 (0.45) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| SCHEMBL9767610 | 0.73 | CA12 (0.45) | FEN1ALDH1A1TSHRCYP2C19PDE4A | |
| Hydrochloric Acid SCHEMBL10722765 | 0.73 | CDK4 (0.50) | FEN1ALDH1A1TSHRCYP2C19PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | claimed |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-04 | — | — | US | claimed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1613318-A4 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-04 | — | — | US | disclosed |
| EP-1613318-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087880-A2 | COMPOUNDS AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094714-A1 | Compounds and their use to treat diabetes and related disorders | IAPP, SLC5A2, SLC5A1 | FEN1 4648/4885ALDH1A1 426/4885TSHR 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.